Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 20, 2021updated 07 Jan 2022 8:49am

FDA grants marketing approval for OrganOx’s metra system

The approval includes the use of metra for liver grafts from donors after circulatory death and after brain death.

The US Food and Drug Administration (FDA) has granted premarket approval (PMA) for OrganOx’s liver normothermic machine perfusion (NMP) metra system.

Fully automated NMP device, the OrganOx metra system is designed to preserve and transport donor livers in a functioning state for transplantation.

The FDA approval includes the use of the transportable device for liver grafts from donors after circulatory death (DCD) and donors after brain death (DBD).

The device is claimed to be the first fully automated NMP system in the world to receive approval from the FDA for preserving donor livers before transplantation.

It provides warm, oxygenated blood and nutrients to the liver during the crucial time between donation and transplantation.

With rugged and robust design, the metra system offers easy transportation and safe storage of donor livers when not in use.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

OrganOx CEO Craig Marshall said: “We are thrilled with this news and excited to be able to bring our technology to the US, which we expect will increase the utilisation of donor organs and thereby reduce waitlist mortality.

“To date, the metra has supported more than 1,200 liver transplants worldwide, with several individual centres in Europe having transplanted more than 100 donor livers using our system.

“There is a clear unmet clinical need for our device in the US where the situation is similar to Europe, with many patients dying on the waitlist and large numbers of donated organs that are not transplanted.”

The company stated that the device has enabled the transplantation teams to assess the donor liver’s function before a transplant.

In August this year, Exact Sciences reported positive data of its Oncoguard Liver liquid biopsy test published in Clinical Gastroenterology and Hepatology.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU